Key Details
Price
$0.99Annual ROE
-507.97%Beta
0.16Events Calendar
Next earnings date:
Mar 26, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 25, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Matt Riley - Director-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Mark Massaro - BTIG Anthony Vendetti - Maxim Group Mike Matson - Needham Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK , Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the American Foregut Society (AFS), a leading society of gastroenterologists and surgeons collaborating to improve patient outcomes, including in esophageal disease, has formally requested that health insurance providers update their medical policies to include the EsoGuard® Esophageal DNA test as a covered service. The open letter, posted on the society website, highlights the critical need for early detection of esophageal precancer (Barrett's Esophagus or BE) to prevent highly lethal esophageal cancer, the strong scientific evidence supporting the use of EsoGuard as a minimally invasive screening alternative to endoscopy, and EsoGuard's incorporation in the practices of AFS physicians.
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2023 Results Conference Call November 14, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode.
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced its Chairman and Chief Executive Officer, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023 at 10:00am EST in New York City.
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Ed Woo - Ascendiant Capital Kyle Mikson - Canaccord Mark Massaro - BTIG Mike Matson - Needham & Co. Operator Good day, and welcome to the Lucid Diagnostics Second Quarter 2023 Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded.
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2023 Results Conference Call May 16, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Alex Vukasin - Canaccord Genuity Mike Matson - Needham Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.
FAQ
- What is the ticker symbol for Lucid Diagnostics?
- Does Lucid Diagnostics pay dividends?
- What sector is Lucid Diagnostics in?
- What industry is Lucid Diagnostics in?
- What country is Lucid Diagnostics based in?
- When did Lucid Diagnostics go public?
- Is Lucid Diagnostics in the S&P 500?
- Is Lucid Diagnostics in the NASDAQ 100?
- Is Lucid Diagnostics in the Dow Jones?
- When was Lucid Diagnostics's last earnings report?
- When does Lucid Diagnostics report earnings?
- Should I buy Lucid Diagnostics stock now?